CompletedPhase 1/2

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

United States55 participantsStarted 2008-06

Plain-language summary

The objective of the present study is to establish the long-term safety of an intra-articular injection of human mesenchymal stem cells (hMSCs) (Chondrogen).

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject must have received an injection in Protocol No. 550 * Subject must have completed the 6-month and final 2-year visit in Protocol No. 550 * Subject must provide written informed consent for entry into the extension study * Subject must provide authorization for use and disclosure of protected health information for entry into the extension study

What they're measuring

Comparison of treatment adverse event rates

Timeframe: Through 3 years

Trial details

NCT IDNCT00702741

SponsorMesoblast International Sàrl

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-09

View on ClinicalTrials.gov More Recovery Following Partial Medial Meniscectomy trials